Pharmacology of Testosterone

Introduction/Overview

Testosterone, a primary endogenous androgen steroid hormone, serves as a cornerstone agent in endocrine pharmacology. Synthesized primarily in the Leydig cells of the testes in males, with smaller contributions from the ovaries and adrenal cortex in females, it functions as both a hormone and a therapeutic drug. The clinical pharmacology of exogenous testosterone encompasses its use as replacement therapy for deficiency states and its application in other medical conditions, while also addressing the significant public health concerns related to its abuse as an anabolic-androgenic steroid. A thorough understanding of its pharmacodynamics, pharmacokinetics, and clinical implications is essential for safe and effective prescribing.

The clinical relevance of testosterone pharmacology is substantial and multifaceted. Hypogonadism, characterized by inadequate testosterone production, affects a considerable portion of the aging male population and can result from various primary or secondary etiologies. Testosterone replacement therapy (TRT) aims to alleviate symptoms and restore physiological function. Beyond replacement, testosterone and its analogs find use in other therapeutic areas, including certain forms of anemia and breast carcinoma. Concurrently, the non-medical use of androgenic anabolic steroids for performance enhancement presents serious risks, necessitating that healthcare professionals be adept at recognizing and managing associated complications.

Learning Objectives

• Describe the biochemical synthesis, chemical classification, and formulation types of exogenous testosterone and its derivatives.
• Explain the molecular mechanism of action of testosterone, including its conversion to active metabolites and its genomic and non-genomic effects on androgen receptor signaling.
• Analyze the pharmacokinetic profiles of major testosterone formulations, including absorption, distribution, metabolism, and excretion, and relate these to dosing regimens.
• Evaluate the approved clinical indications, therapeutic benefits, and potential adverse effects associated with testosterone therapy, including contraindications and monitoring parameters.
• Identify significant drug interactions and special population considerations, such as use in hepatic impairment or pediatric patients, to guide clinical decision-making.

Classification

Testosterone and its related therapeutic agents are classified as androgens or anabolic-androgenic steroids (AAS). This classification is based on their chemical structure, origin, and pharmacological activity.

Chemical Classification and Structure

Testosterone is a steroid hormone derived from cholesterol. Its chemical name is 17β-hydroxyandrost-4-en-3-one. It is a C19 steroid with a cyclopentanoperhydrophenanthrene nucleus. The key functional groups include a 3-keto group (Δ4-3-keto configuration) and a 17β-hydroxyl group, both critical for receptor binding. The inherent structure of native testosterone is rapidly metabolized, which led to the development of synthetic derivatives designed to enhance oral bioavailability, prolong duration of action, or dissociate anabolic from androgenic effects, though complete dissociation has not been achieved clinically.

Therapeutic Formulation Classes

Exogenous testosterone is available in numerous formulations, classified primarily by their route of administration and pharmacokinetic properties.

• Injectable Esters: These are prodrugs created by esterifying the 17β-hydroxyl group with fatty acid chains (e.g., enanthate, cypionate, propionate, undecanoate). The esterification increases lipophilicity, allowing for depot storage in adipose tissue after intramuscular injection. Enzymatic hydrolysis in vivo releases free testosterone. Longer-chain esters like testosterone undecanoate provide extended release profiles.
• Transdermal Systems: This class includes gels, solutions, and patches. Gels and solutions (containing alcohol) deliver testosterone through the skin, with absorption influenced by site of application, skin characteristics, and surface area. Patches provide controlled release through a membrane. These systems aim to mimic physiological diurnal rhythms more closely than injectables.
• Buccal and Nasal Systems: Buccal tablets adhere to the gum, allowing absorption through the oral mucosa, bypassing first-pass hepatic metabolism. Intranasal gels are applied to the nasal vestibule for pulsed absorption.
• Oral Agents: Unmodified testosterone has poor oral bioavailability due to extensive first-pass metabolism. Two main types circumvent this:
  • 17α-Alkylated Derivatives: Compounds like methyltestosterone and fluoxymesterone have an alkyl group at the 17α position, which reduces hepatic degradation. However, this modification is associated with significant hepatotoxicity.
  • Testosterone Undecanoate (Oral): This is an ester dissolved in oil. It is absorbed via the lymphatic system, partially bypassing the portal circulation, which improves bioavailability and reduces liver strain compared to 17α-alkylated drugs.
• Subcutaneous Pellets: Crystalline testosterone pellets are implanted subcutaneously, providing stable hormone release over three to six months.

Mechanism of Action

The pharmacological effects of testosterone are mediated primarily through its interaction with the androgen receptor (AR), a member of the nuclear receptor superfamily. The action involves both classical genomic pathways and faster, non-genomic mechanisms.

Biochemical Activation

Testosterone itself is a prohormone in many tissues. Its intracellular activity is often dependent on conversion to more potent metabolites by the enzymes 5α-reductase and aromatase.

• Conversion to Dihydrotestosterone (DHT): In tissues such as the prostate, skin, and hair follicles, testosterone is irreversibly reduced by 5α-reductase (types I and II) to DHT. DHT has a 2- to 10-fold greater affinity for the AR than testosterone and forms a more stable complex with the receptor. It is considered the primary mediator of androgenic effects in these tissues.
• Conversion to Estradiol: In adipose tissue, bone, brain, and other sites, testosterone can be aromatized by the cytochrome P450 enzyme complex (CYP19A1, aromatase) to 17β-estradiol. This conversion is critical for some of testosterone’s effects, including epiphyseal closure in bones, modulation of libido, and negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis.

Genomic (Slow) Signaling Pathway

This is the primary mechanism for most androgenic and anabolic effects. Free testosterone or DHT diffuses across the plasma membrane and binds to the cytosolic AR. The AR is normally complexed with heat shock proteins (HSPs). Hormone binding induces a conformational change, dissociation of HSPs, dimerization, and phosphorylation. The hormone-AR complex then translocates to the nucleus, binds to specific DNA sequences known as androgen response elements (AREs) in the promoter regions of target genes. This recruitment facilitates the assembly of coregulator complexes (coactivators or corepressors), leading to modulation of gene transcription. The resulting mRNA is translated into proteins that mediate the cellular response, such as increased synthesis of structural proteins, growth factors, or enzymes. This process typically takes hours to days to manifest.

Non-Genomic (Rapid) Signaling Pathway

Testosterone and other androgens can also elicit effects within seconds to minutes, too rapid to involve gene transcription. These effects are mediated by membrane-associated or cytosolic ARs, or potentially through interaction with other receptors like G-protein-coupled receptors. Non-genomic signaling can activate second messenger systems, including increases in intracellular calcium, activation of protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) pathways. These pathways can influence cell motility, neuronal excitability, and vascular tone, and may also modulate the classical genomic pathway through cross-talk.

Physiological and Pharmacological Effects

• Anabolic Effects: Promotion of nitrogen retention and protein synthesis in skeletal muscle, leading to increased muscle mass and strength. Stimulation of erythropoiesis via increased renal production of erythropoietin and direct effects on bone marrow stem cells.
• Androgenic Effects: Development and maintenance of male secondary sexual characteristics (facial/body hair, deepening of voice, sebaceous gland activity). Regulation of sexual function (libido, erectile function) and spermatogenesis (in concert with follicle-stimulating hormone).
• Other Effects: Effects on bone mineral density via stimulation of osteoblast activity and aromatization to estradiol. Influence on mood, cognition, and behavior. Modulation of lipid metabolism (often decreasing HDL cholesterol) and insulin sensitivity.

Pharmacokinetics

The pharmacokinetics of testosterone are highly formulation-dependent, influencing the choice of therapy based on desired serum concentration profiles, convenience, and patient-specific factors.

Absorption

Absorption characteristics vary drastically by route.

• Injectable Esters: Administered via deep intramuscular injection (typically gluteal or deltoid). Absorption from the oily depot is rate-limited by the hydrolysis of the ester bond by tissue esterases. Shorter-chain esters (e.g., propionate) are hydrolyzed rapidly, leading to a large peak (C_max) and short duration (t_1/2 ≈ 0.8 days). Longer-chain esters (e.g., enanthate, cypionate) are released more slowly, with t_1/2 of 4-5 days and dosing intervals of 1-2 weeks. Testosterone undecanoate injection has an even longer t_1/2 (~20 days), allowing for 10-14 week intervals.
• Transdermal: Absorption through the skin is passive and continuous. Bioavailability of gels ranges from 8% to 14%. Application site, skin hydration, and surface area affect absorption. Serum levels can show a diurnal pattern, though less pronounced than endogenous secretion. Transfer to others via skin contact (secondary exposure) is a significant consideration.
• Buccal/Nasal: Buccal systems provide absorption directly into the systemic circulation via the superficial mucosal veins, bypassing first-pass metabolism. Nasal gel is absorbed through the nasal mucosa, resulting in pulsed pharmacokinetics with multiple daily doses required.
• Oral: Unmodified testosterone is poorly absorbed and extensively metabolized to inactive compounds in the gut and liver (first-pass effect >90%). 17α-alkylated derivatives resist hepatic inactivation but carry hepatotoxicity risks. Oral testosterone undecanoate in oil is absorbed via the intestinal lymphatics, partially avoiding first-pass metabolism, and must be taken with a fatty meal to promote lymphatic uptake.
• Subcutaneous Pellets: Provide zero-order release kinetics, where the rate of drug release is constant over time, resulting in very stable serum concentrations for the lifespan of the pellet (3-6 months).

Distribution

In the bloodstream, testosterone is highly bound to plasma proteins. Approximately 40-50% is tightly bound to sex hormone-binding globulin (SHBG) with high affinity, and about 50-60% is loosely bound to albumin. Only 1-3% circulates as free, biologically active hormone. The free hormone hypothesis suggests that this unbound fraction is available for tissue uptake. Conditions that alter SHBG levels (e.g., aging, obesity, liver disease, thyroid disorders) can significantly influence the free testosterone concentration. Testosterone and its esters are widely distributed into tissues, with higher concentrations typically found in androgen-responsive organs.

Metabolism

Testosterone undergoes extensive hepatic metabolism, which is the primary reason for its poor oral bioavailability. Major metabolic pathways include:

1. Oxidation/Reduction: The 17β-hydroxyl group is oxidized to a 17-keto group, producing androstenedione, which can be further reduced to etiocholanolone and androsterone. These are then conjugated.
2. Aromatization: As described, conversion to estradiol by aromatase in various tissues.
3. 5α-Reduction: Conversion to the more potent DHT in target tissues.

The metabolites are primarily conjugated with glucuronic acid or sulfate to form water-soluble compounds for excretion. The metabolism of testosterone esters involves an initial hydrolysis step by esterases in plasma and tissues to liberate free testosterone, which then enters the above pathways.

Excretion

Conjugated metabolites (e.g., testosterone glucuronide) are excreted predominantly in the urine (≈90%), with a smaller fraction eliminated in the bile and feces. The elimination half-life of endogenous free testosterone is relatively short, approximately 10 to 100 minutes. However, the effective half-life of therapeutic formulations is governed by the rate of absorption from the depot (for injections, pellets) or delivery system (for transdermal), making it substantially longer.

Therapeutic Uses/Clinical Applications

The primary goal of testosterone therapy is to achieve and maintain physiological serum concentrations to correct deficiency states and alleviate symptoms. Other uses leverage its anabolic or anti-estrogenic properties.

Approved Indications

• Male Hypogonadism: This is the principal indication. Diagnosis requires both consistent symptoms (e.g., low libido, erectile dysfunction, fatigue, depressed mood, reduced muscle mass) and signs, along with unequivocally low morning serum testosterone levels on at least two occasions. It is categorized as:
  • Primary (Hypergonadotropic): Testicular failure (e.g., Klinefelter syndrome, orchitis, chemotherapy).
  • Secondary (Hypogonadotropic): Pituitary or hypothalamic dysfunction (e.g., pituitary tumors, hyperprolactinemia, idiopathic).

  Therapy aims to restore eugonadal levels, improve symptoms, and prevent long-term sequelae like osteoporosis.

• Delayed Male Puberty: Used cautiously in adolescents with constitutional delay in growth and puberty to stimulate the development of secondary sexual characteristics and accelerate growth. Therapy is typically short-term and uses low doses to avoid premature epiphyseal closure.
• Metastatic Breast Cancer in Women: Historically used as palliative therapy in postmenopausal women with hormone receptor-positive metastatic breast cancer. Its use has largely been supplanted by more modern anti-estrogens and aromatase inhibitors, but it remains an approved option for its anti-estrogenic effects.

Other Medical Uses

• Anemia of Chronic Disease or Bone Marrow Failure: Testosterone’s erythropoietic effect can be beneficial in certain anemias, particularly those associated with renal failure or myelodysplastic syndromes, often when erythropoiesis-stimulating agents are ineffective or contraindicated.
• Wasting Syndromes: In conditions associated with catabolism and severe weight loss, such as advanced HIV/AIDS or extensive burns, testosterone may be used to increase lean body mass and strength, though its role is adjunctive.
• Gender-Affirming Hormone Therapy: Testosterone is a fundamental component of masculinizing hormone therapy for transgender men and some non-binary individuals to induce and maintain male secondary sex characteristics.

Adverse Effects

The adverse effect profile of testosterone therapy is largely an extension of its physiological and pharmacological actions. Risk is influenced by dose, formulation, patient age, baseline health status, and the presence of predisposing conditions.

Common Side Effects

• Androgenic Skin Effects: Acne vulgaris and increased oiliness of skin due to stimulation of sebaceous glands. Acceleration of male-pattern baldness in genetically predisposed individuals.
• Erythrocytosis: A dose-dependent increase in hemoglobin and hematocrit is one of the most frequent laboratory abnormalities. While mild increases are common, marked polycythemia (hematocrit >54%) increases the risk of thromboembolic events and may require dose reduction, discontinuation, or therapeutic phlebotomy.
• Fluid Retention: Mild peripheral edema can occur due to sodium and water retention, which may exacerbate pre-existing hypertension, congestive heart failure, or renal impairment.
• Gynecomastia: Resulting from the peripheral aromatization of testosterone to estradiol, particularly if there is an imbalance between androgen and estrogen effects.
• Local Reactions: Application site reactions for transdermal products (pruritus, erythema). Pain or sterile abscess at injection sites. Cough immediately after injection of testosterone undecanoate, attributed to pulmonary oil microembolism.

Serious and Rare Adverse Reactions

• Cardiovascular Risk: The association between TRT and major adverse cardiovascular events (MACE) remains controversial and is an area of active research. Some studies have suggested an increased risk of myocardial infarction, stroke, and venous thromboembolism, particularly in older men with pre-existing cardiovascular disease. Proposed mechanisms include erythrocytosis, increased vascular inflammation, and adverse lipid profile changes (reduction in HDL cholesterol). A careful benefit-risk assessment is mandatory in patients with significant cardiovascular risk factors.
• Prostate Events: Testosterone therapy is contraindicated in men with prostate cancer due to the potential for stimulating growth. In men without cancer, TRT may increase prostate-specific antigen (PSA) levels and potentially exacerbate symptoms of benign prostatic hyperplasia (BPH), including lower urinary tract symptoms. It does not appear to increase the risk of developing prostate cancer, but monitoring is essential.
• Sleep Apnea: May induce or worsen obstructive sleep apnea, possibly due to increased upper airway edema or effects on ventilatory control.
• Hepatotoxicity: Primarily associated with 17α-alkylated oral androgens (methyltestosterone, oxandrolone). Can range from reversible elevations in liver transaminases to cholestatic jaundice, peliosis hepatis (blood-filled cysts in the liver), and hepatocellular neoplasms. This risk is minimal with non-alkylated testosterone formulations (esters, transdermals).
• Psychiatric Effects: May precipitate or exacerbate aggression, irritability, manic symptoms, or depression in susceptible individuals.
• Infertility and Testicular Atrophy: Exogenous testosterone suppresses the HPG axis via negative feedback on the hypothalamus and pituitary, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. This leads to decreased intratesticular testosterone and impaired spermatogenesis, causing oligospermia or azoospermia and testicular shrinkage. This effect is usually reversible upon discontinuation but may persist for many months.

Warnings and Contraindications

Testosterone carries a black box warning regarding the risk of arterial and venous thrombotic events. It is contraindicated in men with breast cancer or known or suspected prostate cancer. Absolute contraindications also include severe cardiac, hepatic, or renal disease, and untreated severe obstructive sleep apnea. Relative contraindications include elevated hematocrit, severe BPH, and uncontrolled heart failure.

Drug Interactions

Testosterone can interact with several classes of medications, altering its own efficacy or the effects of co-administered drugs.

Major Drug-Drug Interactions

• Anticoagulants (Warfarin): Testosterone may potentiate the anticoagulant effect of warfarin, possibly by increasing clotting factor catabolism or reducing synthesis of vitamin K-dependent clotting factors. Close monitoring of the International Normalized Ratio (INR) is required when initiating or discontinuing testosterone therapy.
• Corticosteroids and ACTH: Concurrent use may exacerbate fluid retention and edema.
• Insulin and Oral Hypoglycemics: Androgens may decrease blood glucose and enhance insulin sensitivity, potentially increasing the risk of hypoglycemia in diabetic patients. Dosage adjustments of antidiabetic agents may be necessary.
• Drugs Affecting Testosterone Metabolism:
  • Enzyme Inducers (e.g., phenobarbital, phenytoin, rifampin, carbamazepine): These agents increase the hepatic metabolism of testosterone, potentially reducing its serum concentration and therapeutic effect.
  • Enzyme Inhibitors (e.g., ketoconazole, protease inhibitors): May decrease testosterone metabolism, potentially increasing its exposure and risk of adverse effects.
• Other Hormonal Agents: Concurrent use with other androgens or anabolic steroids is additive and increases toxicity. Testosterone may antagonize the effects of estrogens or progestins.

Contraindications

As noted, contraindications include prostate or male breast cancer, pregnancy (due to risk of virilization of a female fetus), severe cardiorenal or hepatic disease, and untreated sleep apnea. Caution is advised with a history of hypercalcemia (in breast cancer patients) or pre-existing polycythemia.

Special Considerations

Pregnancy and Lactation

Testosterone is contraindicated during pregnancy (FDA Pregnancy Category X). Exposure of a female fetus can result in virilization, including clitoromegaly and labial fusion. It is not indicated for use in women of childbearing potential unless they are using highly effective contraception. Testosterone is excreted in human milk, and its use during breastfeeding is not recommended due to potential adverse effects on the infant.

Pediatric Use

Use is restricted to males with delayed puberty due to confirmed hypogonadism. Therapy must be managed by a specialist. The primary concerns are the acceleration of bone age advancement leading to premature closure of epiphyses and compromised final adult height, and the potential for premature sexual development. Low-dose, intermittent regimens are typically employed, with careful monitoring of growth velocity and bone age.

Geriatric Use

Older men may be more susceptible to adverse effects, particularly prostate-related events (BPH symptoms, increased PSA), erythrocytosis, and cardiovascular events. The diagnosis of hypogonadism in older age can be challenging due to overlapping symptoms with normal aging and chronic illness. The benefits of TRT for age-related decline in testosterone (“andropause”) in the absence of classical hypogonadism are not well-established, and risks may be increased. A conservative approach with clear indications is warranted.

Renal Impairment

Patients with chronic kidney disease (CKD), especially those on dialysis, often have hypogonadism. Testosterone can be used but requires careful monitoring. Fluid retention may exacerbate hypertension or edema. The risk of erythropoiesis is a potential benefit for associated anemia but must be monitored closely to avoid polycythemia. Dose adjustment is not typically required for most formulations, but caution is advised.

Hepatic Impairment

Patients with liver disease may have altered metabolism of testosterone and increased risk of adverse effects. Serum binding proteins (SHBG, albumin) may be altered, affecting free testosterone levels. 17α-alkylated androgens are absolutely contraindicated. Non-alkylated testosterone (transdermal, injectable esters) may be used with extreme caution and frequent monitoring in patients with mild to moderate impairment, but are generally avoided in severe hepatic disease.

Summary/Key Points

• Testosterone is the primary endogenous androgen, and its exogenous administration serves as replacement therapy for hypogonadism and has other specialized medical uses.
• Its mechanism involves activation of the intracellular androgen receptor, often after conversion to the more potent dihydrotestosterone (via 5α-reductase) or to estradiol (via aromatase), mediating both genomic and non-genomic effects.
• Pharmacokinetics are entirely formulation-dependent. Injectable esters provide depot release, transdermal systems offer more physiological delivery, and oral non-alkylated testosterone undecanoate bypasses first-pass metabolism via lymphatic absorption.
• The primary therapeutic goal in hypogonadism is to alleviate symptoms and restore physiological function by normalizing serum testosterone levels, with careful attention to individual patient factors.
• Significant adverse effects include erythrocytosis, acne, gynecomastia, suppression of the HPG axis leading to infertility, and potential exacerbation of BPH symptoms. A possible increased cardiovascular risk requires careful patient selection and monitoring.
• Serious hepatotoxicity is associated primarily with 17α-alkylated oral androgens and is rare with other formulations.
• Major drug interactions include potentiation of warfarin anticoagulation and altered metabolism by hepatic enzyme inducers or inhibitors.
• Special caution is required in pediatric patients to avoid premature epiphyseal closure, in geriatric patients due to increased prostate and cardiovascular risks, and in patients with hepatic or renal impairment. It is contraindicated in pregnancy.

Clinical Pearls

• Diagnosis of hypogonadism requires both consistent clinical symptoms and unequivocally low morning total testosterone levels, measured on at least two occasions. Assessment of free testosterone may be helpful when SHBG levels are abnormal.
• The choice of testosterone formulation should be a shared decision with the patient, balancing pharmacokinetic profiles, convenience, cost, and individual risk factors (e.g., transdermal gels may be preferred in patients with heart failure to avoid the fluid retention spikes associated with injectable esters).
• Baseline and ongoing monitoring is critical: including hematocrit (at 3-6 months, then annually), PSA and digital rectal exam in men over 40 or with risk factors, and assessment of symptomatic response and adverse effects.
• Patients should be counseled on the expected benefits, potential risks (including cardiovascular and prostate safety discussions), and the high likelihood of suppressed spermatogenesis with therapy.
• In patients desiring fertility, TRT is generally contraindicated. Alternative approaches, such as selective estrogen receptor modulators (e.g., clomiphene) or gonadotropins, should be considered to stimulate endogenous testosterone and sperm production.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.